26 completed, 8 terminated, 3 withdrawn, 1 active not recruiting. 27 Phase 2, 9 Phase 1, 3 Phase 4, 1 Early Phase 1, 1 Not applicable.
Follow denileukin diftitox: new trials by email Literature Review of denileukin diftitox trials Research Report on denileukin diftitox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) Remitoro - Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous | Completed | Eisai Inc. | 118 | 2021-05-24 | 2023-12-12 | |
| E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma denileukin diftitox (E7777) - Peripheral T-Cell Lymphoma | Phase 1 | Completed | Eisai Co., Ltd. | 13 | 2011-07-01 | 2018-11-23 |
| Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation Denileukin Diftitox (Ontak) - Multiple Myeloma | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 2 | 2010-11-01 | 2017-06-20 |
| Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) Natural Killer Cells, Fludarabine, Cyclophosphamide - Leukemia, Myelogenous, Acute | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 15 | 2010-07-01 | 2017-12-28 |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Denileukin diftitox - Stage IIIC Melanoma, Stage IV Melanoma | Phase 2 | Completed | Eisai Inc. | 75 | 2010-06-22 | 2022-04-13 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer Denileukin Diftitox/SC Pegylated IFNα-2a - Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer | Phase 2 | Terminated | The University of Texas Health Science Center at San Antonio | 2 | 2009-06-01 | 2018-04-10 |
| Denileukine Diftitox for Relapsed ALCL Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide - Anaplastic Large-Cell Lymphoma | Phase 2 | Withdrawn | Columbia University | 2008-12-01 | 2013-05-15 | |
| A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer Ontak - Metastatic Pancreatic Cancer | Phase 2 | Terminated | Loyola University | 7 | 2008-10-01 | 2016-09-29 |
| Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection - Peripheral T-Cell Lymphoma | Phase 2 | Terminated | University of California, San Francisco | 21 | 2008-07-01 | 2020-04-27 |
| Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma denileukin diftitox, rituximab - Lymphoma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 24 | 2008-04-01 | 2017-04-18 |
| Vaccination Plus Ontak in Patients With Metastatic Melanoma 4-peptide melanoma vaccine, Ontak - Melanoma | Phase 2 | Terminated | University of Chicago | 17 | 2007-04-23 | 2021-01-26 |
| A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Ontak - Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 19 | 2007-02-01 | 2018-03-27 |
| Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma denileukin diftitox, cyclophosphamide, cytarabine - Lymphoma | Not applicable | Withdrawn | University of Miami | 2007-02-01 | 2016-12-15 | |
| Phase II Trial of Ontak With Metastatic Melanoma Denileukin diftitox - Malignant Melanoma | Phase 2 | Completed | James Graham Brown Cancer Center | 69 | 2006-03-01 | 2014-09-05 |
| A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy - Peripheral T-Cell Lymphoma | Phase 2 | Completed | Yale University | 49 | 2005-11-01 | 2015-02-27 |
| Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells - Breast Cancer, Colorectal Cancer | Phase 1 | Completed | H. Kim Lyerly | 24 | 2005-09-01 | 2012-11-12 |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment ONTAK, flow cytometry, immunohistochemistry staining method - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Completed | University of Washington | 15 | 2005-09-01 | 2018-12-05 |
| Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells IL-2 secreting and hCL4OL-expressing autologous B-CLL cells, IL-2, CD40L - CHRONIC LYMPHOCYTIC B-LEUKEMIA | Phase 1 | Withdrawn | Baylor College of Medicine | 2005-09-01 | 2012-05-21 |
Showing 20 of 40. Sign in to see all of them.
Lymphoma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, T-Cell, Cutaneous (6) · Carcinoma, Ovarian Epithelial (5) · Lymphoma, T-Cell, Peripheral (5) · Melanoma (5) · Lymphoma, Follicular (4) · Mycosis Fungoides (4) · Sezary Syndrome (4) · Breast Neoplasms (3) · Fallopian Tube Neoplasms (3) · Leukemia (3) · Lymphoma, Large B-Cell, Diffuse (3) · Neoplasms (3) · Breast Neoplasms, Male (2)
Eisai Inc. (10) · University of Washington (3) · National Cancer Institute (NCI) (2) · The University of Texas Health Science Center at San Antonio (2) · Alexander B Olawaiye, MD (1) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · Columbia University (1) · Eastern Cooperative Oncology Group (1) · Eisai Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · H. Kim Lyerly (1) · James Graham Brown Cancer Center (1) · Jonsson Comprehensive Cancer Center (1)
United States (36) · Australia (3) · Canada (3) · Austria (2) · Germany (2) · Japan (2) · Poland (2) · Russia (2) · Switzerland (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Netherlands (1)
Elyane Lombardy, M.D. (4) · Francine Foss, M.D. (2) · Lupe Salazar (2) · Timothy M. Kuzel, MD (2) · Alexander Olawaiye, MD (1) · Arthur E. Frankel, MD (1) · Debby Henkens (1) · Gary Palmer, MD (1) · Jason Chesney, MD, PhD (1) · Jeffrey S. Miller, M.D. (1) · Lauren C. Pinter-Brown, MD (1) · Lawrence Kaplan, MD (1) · Malcolm K Brenner, MD (1) · Margo Shoup, MD (1)
PMID 23770157, PMID 16586495, PMID 17943599, PMID 18334033, PMID 18519811, PMID 19443659, PMID 19925875, PMID 20541024, PMID 22015775, PMID 22165955, PMID 22383800, PMID 23278639, PMID 24719405, PMID 27330808, PMID 29363235, PMID 32632956, PMID 38022532, PMID 39362046, PMID 42605024
K12CA076930 (1), P30CA060553 (1), R21CA137647 (1), U01HL069294 (1)